Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

Autor: van den Bent, MJ, Wefel, JS, Schiff, D, Taphoorn, MJB, Jaeckle, K, Junck, L, Armstrong, T, Choucair, A, Waldman, AD, Gorlia, T, Chamberlain, M, Baumert, BG, Vogelbaum, MA, Macdonald, DR, Reardon, DA, Wen, PY, Chang, SM, Jacobs, AH

Publikováno v: In Lancet Oncology 2011 12(6):583-593

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group

Autor: Alexander, Bm, Brown, Pd, Ahluwalia, Ms, Aoyama, H, Baumert, Bg, Chang, Sm, Gaspar, Le, Kalkanis, Sn, Macdonald, Dr, Mehta, Mp, Soffietti, R, Suh, Jh, van den Bent MJ, Vogelbaum, Ma, Wefel, Js, Lee, Eq, Wen, Py, Response Assessment in Neuro-Oncology (RANO) group

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______970::09faf3eadab6c9ac8cbf3beaa2a8d387
http://hdl.handle.net/2318/1656215

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Autor: Ellingson, BM, Bendszus, M, Boxerman, J, Barboriak, D, Erickson, BJ, Smits, M, Nelson, SJ, Gerstner, E, Alexander, B, Goldmacher, G, Wick, W, Vogelbaum, M, Weller, M, Galanis, E, Kalpathy-Cramer, J, Shankar, L, Jacobs, P, Pope, WB, Yang, D, Chung, C, Knopp, MV, Cha, S, Van Den Bent, MJ, Chang, S, Al Yung, WK, Cloughesy, TF, Wen, PY, Gilbert, MR, Whitney, A, Sandak, D, Musella, A, Haynes, C, Wallace, M, Arons, DF, Kingston, A

Publikováno v: Ellingson, BM; Bendszus, M; Boxerman, J; Barboriak, D; Erickson, BJ; Smits, M; et al.(2015). Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 17(9), 1188-1198. doi: 10.1093/neuonc/nov095. UCSF: Retrieved from: http://www.escholarship.org/uc/item/2dw3q7jq

© 2015 The Author(s). A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::21818591e0c19b3cbcd3a4fe500b5dbe
http://www.escholarship.org/uc/item/2dw3q7jq

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Autor: Stupp, R, Mason, Wp, VAN DEN BENT MJ, Weller, M, Fisher, B, Taphoorn, Mj, Belanger, K, Brandes, Aa, Marosi, C, Bogdahn, U, Curschmann, J, Janzer, Rc, Ludwin, Sk, Gorlia, T, Allgeier, A, Lacombe, D, Cairncross, Jg, Eisenhauer, E, Mirimanoff, Ro, Soffietti, Riccardo, NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______970::fe7645014404d82afee6963266bb78f9
http://hdl.handle.net/2318/35760

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel

Autor: L. C. Pronk, van Putten Wl, van den Bent Mj, P. H. E. Hilkens, Jaap Verweij, Gerrit Stoter

Publikováno v: Anti-Cancer Drugs, 9, 759-764. Lippincott Williams & Wilkins

Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff4a47b8c947737747caacd354f08ba0
https://pubmed.ncbi.nlm.nih.gov/9840720